

Psoriasis and metabolic disease: epidemiology and pathophysiology

Rahat S. Azfar^a and Joel M. Gelfand^{a,b}

^aDepartment of Dermatology and ^bCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Correspondence to Joel M. Gelfand, MD, MSCE, 3600 Spruce Street 2 Maloney Building, Philadelphia, PA 19104, USA
E-mail: Joel.Gelfand@uphs.upenn.edu

Current Opinion in Rheumatology 2008, 20:416–422

Purpose of review

The scientific literature linking psoriasis to metabolic syndrome, and its components, as well as atherosclerosis and myocardial infarction has rapidly expanded. Increasingly, epidemiological studies are establishing the directionality of these associations and psoriasis' role as an independent risk factor in developing these outcomes.

Recent findings

Psoriasis is associated with metabolic syndrome, and its components, such as obesity, diabetes, and hypertension. Obesity has been shown to be an independent risk factor for the development of psoriasis, and is also associated with more severe psoriasis. Psoriasis is associated with diabetes, coronary artery disease, and an increased risk for myocardial infarction independent of traditional risk factors for these disorders. These phenotypically diverse conditions share similar pathologic changes such as chronic inflammation, angiogenesis, oxidative stress, and selected susceptibility genes and loci.

Summary

The broad literature linking psoriasis to metabolic disorders has led to changes in standard of care recommendations for patients with psoriasis. In particular, practitioners are encouraged to screen psoriasis patients, especially when disease is severe, for metabolic disorders and cardiovascular risk factors and institute appropriate prevention strategies. Additional studies investigating the role of psoriasis activity and severity as an independent risk factor for developing metabolic disorders, atherosclerosis, and myocardial infarction and the role of psoriasis treatment in altering the risk of developing these serious morbidities are urgently needed.

Keywords

epidemiology, inflammation, metabolic syndrome, myocardial infarction, psoriasis

Curr Opin Rheumatol 20:416–422.
© 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins
1040-8711

Introduction

Psoriasis is a chronic inflammatory skin disorder affecting 1–3% of the population. It is associated with impairments in health related quality of life even in mild cases, and excess mortality in severe cases [1••]. Psoriasis is characterized by epidermal hyperproliferation, abnormal keratinocyte differentiation, angiogenesis with blood vessel dilatation, and excess Th-1 and Th-17 inflammation. Increasingly, associations between psoriasis and metabolic diseases such as obesity, diabetes, and cardiovascular disease have been recognized. Epidemiological studies have established these associations and increasingly they are determining the directionality of the associations and the role of psoriasis as an independent risk factor for these outcomes. Similarly, advances in the knowledge of the pathogenesis of these seemingly diverse diseases have discovered common physiological pathways that may provide the biological plausibility of the associations discovered through epidemiological

studies. In this review, we will explore the recent epidemiologic evidence linking psoriasis to metabolic diseases and summarize the common elements of pathophysiology underlying these conditions.

Epidemiology

Many epidemiologic studies with varied designs link psoriasis to systemic metabolic co-morbidities such as obesity, hyperlipidemia, cardiovascular disease, and diabetes. We will discuss the most recent epidemiologic evidence linking psoriasis to several of these co-morbidities below (see Table 1 for a summary of these studies).

Obesity, diabetes, hyperlipidemia, and the metabolic syndrome

The metabolic syndrome is a constellation of lipid and nonlipid cardiovascular risk factors of metabolic origin. Multiple groups have issued slightly different criteria for definition of the metabolic syndrome. The most widely

Table 1 Summary of recent epidemiological data on relationship between psoriasis and metabolic diseases

| Study | Design | Population | Control for confounding factors | Result |
|---------------------|---------------------|---|--|--|
| Akhyani [6] 2006 | Cross-sectional | 50 cases and 50 controls from Iran selected from hospital clinic | Controlled for confounding by adjustment for age, gender, BMI and through exclusion criteria for comorbidities | Psoriasis patients with worse levels of TC, TG, LDL, VLDL but not HDL than controls |
| Boehncke [18*] 2007 | Cross-sectional | 39 consecutive psoriasis patients referred to a dermatology unit | None | Weak correlation between PASI score and insulin secretion, and resistin. No association of PASI with BMI, vessel wall thickness, glucose, HOMA |
| Cohen [8] 2007 | Cross-sectional | Managed care database with 340 psoriasis patients and 6643 controls s/p hernioplasty or appendectomy in Israel | Controlled for confounding via adjustment for age, gender, smoking | Increased prevalence of DM in psoriasis patients compared with controls |
| Cohen [5] 2008 | Cross-sectional | Managed care medical record database with 16 851 psoriasis patients and 48 681 controls without psoriasis in Israel | Controlled for confounding via adjustment for age and gender, smoking | No statistically significant association for psoriasis and IHD, HTN, dyslipidemia, and obesity |
| Farshchian [9] 2007 | Cross-sectional | 30 patients from hospital based dermatology clinic in Iran vs. age, sex, BMI matched healthy controls | Controlled for confounding via exclusion of secondary conditions influencing carbohydrate or lipid metabolism | Increased prevalence of metabolic syndrome, HTN, obesity in psoriasis patients |
| Gelfand [23] 2006 | Cohort | Population based cohort of 130 976 patients 20–90 year old with psoriasis versus 556 995 practice matched nonpsoriasis controls from UK medical record database | Controlled for confounding via adjusting for diagnoses of cardiovascular risk factors (BMI, diabetes, HTN, hyperlipidemia, smoking, age, sex) | No significant differences in lipid profile or fasting blood sugar |
| Gisondi [3*] 2007 | Cross-sectional | 3 university hospital based Italian clinics with 338 psoriasis cases and 334 consecutive dermatology controls | Controlled for confounding via inclusion and exclusion criteria and adjustment for age and gender | Patients with mild and severe psoriasis are at increased risk of MI independent of traditional cardiovascular risk factors |
| Han [19] 2006 | Cross-sectional | US health insurance database; 3066 patients with psoriatic arthritis (PsA) vs. remaining patients in database | Controlled for confounding via adjustment for age and sex | Increased prevalence of metabolic syndrome in psoriasis patients compared to controls |
| Huerta [15**] 2007 | Nested case-control | 3994 incident cases of psoriasis and random sample of 10 000 controls from General Practice Research Database in UK | Controlled for confounding via adjustment for sex, age, calendar year, smoking, and visits to the GP in the last year | No difference in prevalence of low HDL, HTN, or fasting plasma glucose |
| Ludwig [22**] 2007 | Cross-sectional | 32 discharged German hospital patients with severe psoriasis versus age, sex matched database controls | Controlled for confounding by adjustment for age, gender, smoking, family history of cardiovascular disease, diabetes, hypertension, BMI, total cholesterol, triglycerides, C-reactive protein. Excluded patients with a history of cardiovascular disease | Weak, positive correlation of psoriasis severity and hypertriglyceridemia |
| Mallbris [10] 2006 | Cross-sectional | 200 Swedish patients with new diagnosis of psoriasis compared to 285 recruited from a Swedish population registry | Controlled for confounding via excluding patients on medications affecting serum lipids and adjustment for age, sex, smoking, physical exercise, alcohol use, BMI, systolic blood pressure | No association between psoriasis severity and waist circumference, blood pressure, and fasting glucose |

(continued over/leaf)

Table 1 (continued)

| Study | Design | Population | Control for confounding factors | Result |
|----------------------|-----------------|---|---|---|
| Neimann [11] 2006 | Cross-sectional | UK based medical record database of: 127 706 patients with mild psoriasis compared to 465 252 subjects without psoriasis 3854 patients with severe psoriasis compared to 14 065 subjects without psoriasis | Controlled for confounding via adjustment for age, gender, diabetes, hypertension, hyperlipidemia, obesity, and smoking | Patients with mild psoriasis with adjusted odds ratios of DM, HTN, hyperlipidemia, obesity, smoking higher than controls; patients with severe psoriasis with adjusted odds ratios of DM, obesity, smoking higher than controls, no adjusted association of HTN or hyperlipidemia in this group Proportion of patients with diabetes and atherosclerosis increased in patients with psoriasis over controls Psoriasis was independently associated with: DM, CAD, HTN, hyperlipidemia, obesity |
| Shapiro [17] 2007 | Cross-sectional | Managed healthcare record database in Israel with 46 095 psoriasis patients and 1 579 037 patients without psoriasis | Controlled for confounding via adjustment for age and gender | |
| Sommer [4] 2006 | Cross-sectional | 625 hospitalized psoriasis patients and 1044 patients undergoing surgical treatment of stage I melanoma from Germany | Controlled for confounding via adjustment for age, gender, smoking and alcohol consumption | |
| Solak Tekin [7] 2007 | Cross-sectional | Hospital based outpatient dermatology clinic in Turkey with 84 untreated psoriasis patients versus 40 age-sex matched health controls from the general population | Controlled for confounding using exclusion criteria for co-morbidities that affect lipids. | Higher overall lipid levels and lower HDL in patients with psoriasis than in controls |

BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; CVD, cardiovascular disease; DM, diabetes mellitus; HDL, high density lipoprotein; HOMA, homeostasis model adjustment; HTN, hypertension; IHD, ischemic heart disease; LDL, low density lipoprotein; MI, myocardial infarction; PASI, psoriasis area and severity index; PVD, peripheral vascular disease; TC, total cholesterol; TG, triglycerides; VLDL, very low density lipoprotein.

accepted criteria are issued by the Adult Treatment Panel III which defines metabolic syndrome as the presence of at least three of the following conditions; abdominal obesity [waist circumference >102 cm (40 in) men; >88 cm (35 in) women], elevated serum triglycerides [≥ 150 mg/dl (1.7 mmol/l) or under treatment], low HDL cholesterol [men <40 mg/dl (1 mmol/l); women <50 mg/dl (1.3 mmol/l) or under treatment], elevated blood pressure (>130/85 mmHg or under treatment), and an elevated fasting glucose (>110 mg/dL or under treatment) [2].

In a cross-sectional study, Gisondi *et al.* [3[•]] reported that among patients from an Italian dermatology clinic, psoriasis patients not on systemic medications had a higher prevalence of metabolic syndrome (defined by ATP III criteria) versus general dermatology patients after controlling for sex and age [30.1% vs. 20.6%, odds ratio (OR) 1.65, 95% confidence interval (CI) 1.16–2.35]. However, when looking at individual components of the metabolic syndrome, only hypertriglyceridemia and abdominal obesity were more significantly prevalent in patients with psoriasis than in nonpsoriatics. Furthermore, hospitalized psoriasis patients vs. hospitalized melanoma patients in Germany were found to have increased prevalence of metabolic syndrome on the basis of a modified version of the WHO definition, (OR 5.92, 95% CI 2.78–12.8) when adjusted for age and sex [4]. Although few studies have directly evaluated the prevalence of metabolic syndrome in patients with psoriasis, multiple studies have evaluated the prevalence of various components of this syndrome.

Dyslipidemia

Several cross-sectional studies demonstrate an association of psoriasis and dyslipidemia. A cross-sectional study of 16 851 psoriasis patients treated with either PUVA or oral retinoids compared with 48 681 enrollees in Clalit Health Services in Israel demonstrated increased total cholesterol and triglycerides, decreased HDL, and no alteration in LDL in psoriasis patients compared to controls [5]. In a hospital clinic based cross-sectional study in Iran psoriasis patients (mean BSA 42%) were shown to have significantly higher mean levels of triglycerides, total cholesterol, LDL, and VLDL but no alteration in HDL [6]. A cross-sectional study of 84 psoriatic patients attending an outpatient hospital based clinic in Turkey compared with 40 age and sex matched healthy controls from the community demonstrated higher mean total cholesterol, triglycerides, and LDL, and lower mean HDL for the psoriasis patients versus controls respectively. These differences were significantly influenced by gender, with male patients having no differences from controls in HDL levels and female patients having no significant differences from controls in total cholesterol, triglyceride, and LDL levels [7]. In addition, several

cross-sectional studies using varying populations and analytic approaches have found an association between psoriasis and an increased prevalence of diagnoses of hyperlipidemia [4,5,8].

Several studies have failed to find consistent associations of psoriasis with dyslipidemia. A cross-sectional study of 30 psoriasis patients (mean PASI 10.0) attending a hospital based outpatient clinic in Iran compared with 30 sex, age, and BMI matched healthy controls found no association between psoriasis and alteration in fasting blood sugar, triglycerides, total cholesterol, LDL, HDL, and VLDL [9]. Furthermore, a case-control study of 200 recent onset predominantly mild psoriasis patients attending a dermatology clinic in Stockholm and 285 community based controls demonstrated only modest increases in total cholesterol and lipoprotein A-I in psoriasis patients when controlling for age, gender, smoking, exercise, alcohol use, BMI, and systolic blood pressure. Mean HDL levels were actually higher in psoriasis patients and no association of psoriasis and alterations in VLDL, LDL, triglycerides, and Apo B was observed in adjusted analyses [10]. Finally, a population-based cross-sectional study of greater than 130 000 psoriasis patients in the UK demonstrated that although psoriasis is associated with diagnoses of hyperlipidemia, the association diminishes and becomes nonsignificant when controlling for conditions which influence lipids such as obesity and diabetes [11].

Obesity

Numerous studies have implicated an association between obesity and psoriasis based on cross-sectional studies [3[•],4,5,8,11,12[•],13]. More recent studies have established that obesity may occur prior to the onset of psoriasis and be risk factor for development of the disease. A large cohort study of over 78 000 nurses from the US demonstrated a 'dose-response' relationship for obesity on the risk of developing incident psoriasis [14^{••}]. Similarly, a cohort study from the General Practice Research Database in the UK of almost 4000 incident cases of psoriasis confirmed that obesity is an independent risk factor for developing psoriasis [15^{••}]. Additionally, in a case-control study of 560 psoriasis patients seen by dermatologists, obesity was also found to be an independent risk factor for the development of psoriasis [16]. Finally, cross-sectional studies indicate that increasing BMI is associated with greater degrees of psoriasis severity [11,13].

Diabetes

Several cross-sectional studies in various settings have observed an increased prevalence of diabetes in patients with psoriasis [4,8,17]. The increased prevalence of diabetes in patients with psoriasis was independent of traditional diabetes risk factors such as obesity and

dyslipidemia in a large, population-based cross-sectional study in the UK [11]. A small cross-sectional study demonstrated weak, but statistically significant associations between psoriasis severity and markers of insulin resistance such as insulin secretion and serum resistin [18[•]].

Hypertension

Several cross-sectional studies in various settings have found an increased prevalence of hypertension in patients with psoriasis [5,19]. Large, population based cross-sectional studies have not observed a significant association between psoriasis and hypertension when controlling for risk factors such as obesity and smoking [11].

Cardiovascular disease

Multiple studies have found psoriasis to be associated with cardiovascular disease including atherosclerosis and thrombosis (e.g. myocardial infarction) [20,21]. A cross-sectional study of 32 patients with severe psoriasis (defined as >10 year history of plaque-type psoriasis verified by a dermatologist and with >2 episodes of systemic or inpatient treatment) and 32 matched outpatient controls evaluated the prevalence of coronary artery disease using spiral computed tomography to measure coronary artery calcification. Severe psoriasis patients had a higher prevalence of coronary artery disease (CAD) compared with controls (59% vs. 28% respectively, $P=0.02$), and had more severe CAD based on the coronary artery calcification scores. Importantly, psoriasis independently predicted CAD when controlling for cardiovascular risk factors [22^{••}].

A population-based cohort study of greater than 130 000 patients with psoriasis in the UK demonstrated an increased relative risk of myocardial infarction (MI), even when controlling for major cardiovascular risk factors. In particular, younger patients with severe psoriasis (defined as having received systemic psoriasis treatment) had the highest relative risks of MI. For example, a 30-year-old patient with severe psoriasis had a 3.1 (95% CI 2.0–4.9) relative risk of MI, whereas a 60-year-old patient with severe psoriasis had a 1.36 (95% CI 1.1–1.6) relative risk [23].

Pathophysiology

Psoriasis is a prototypical Th-1 inflammatory disease characterized by expansion and activation of Th-1 T cells, antigen presenting cells, and Th-1 cytokines. Similarly, chronic Th-1 inflammation is an important to the pathophysiology of obesity, metabolic syndrome, diabetes, atherosclerosis, and MI. For example, circulating levels of Th-1 cytokines, adhesion molecules such as ICAM-1 and E-selectin, and angiogenic factors, such as

vascular endothelial growth factor (VEG-F) are elevated in psoriasis, obesity, and coronary artery disease [24[•],25]. The inflammatory mediators of these conditions have pleiotropic effects on diverse processes such as angiogenesis, insulin signaling, adipogenesis, lipid metabolism, immune cell trafficking, and epidermal proliferation. Therefore, the metabolic aspects of chronic Th-1 inflammation, angiogenesis, and epidermal hyperproliferation in psoriasis have the potential to impact other conditions such as diabetes, atherosclerosis, and thrombosis. Conversely, inflammatory molecules and hormones produced in conditions such as obesity, diabetes and atherosclerosis may influence the pathogenesis of psoriasis by promoting susceptibility to the development of psoriasis or through increasing the severity of established psoriasis. Additionally, underlying the immune abnormalities shared by these disorders is a complex role for genetics in promoting their development. Here, we will briefly review abnormalities in inflammation, angiogenesis, metabolism, and genetics that are common to these phenotypically distinct disorders.

Chronic inflammation can lead to dysfunction in a variety of organ systems. Th-1 inflammatory cytokines such as TNF- α are elevated in the skin and blood of patients with psoriasis and are critical to recruiting T cells to the skin and joints, promoting angiogenesis, and epidermal hyperproliferation. Similarly, TNF- α is secreted in adipose tissue and is an important feature of the chronic low-level inflammation seen in obesity [14^{••}]. Insulin resistance, which is common to psoriasis and the metabolic syndrome, may be mediated in part through inflammatory cytokines such as TNF. For example, TNF may lead to insulin resistance through a variety of pathways such as impairing insulin signaling by inhibiting the tyrosine kinase activity of the insulin receptor; by activating peroxisome proliferator-activated receptor (PPAR) δ which promotes epidermal proliferation and modulates adipogenesis and glucose metabolism; and by suppressing adiponectin secretion from adipocytes, which is an important anti-inflammatory molecule that also functions in regulating insulin sensitivity [26[•],27,28]. Furthermore, chronic inflammation in psoriasis leads to increased insulin-like growth factor-II (IGF-II) in the skin and blood of psoriasis patients [29[•]]. IGF-II promotes epidermal proliferation and is also implicated in promoting atherosclerosis, in modulating body fat mass and lipid metabolism in mice, and is linked to diabetes and hyperlipidemia in animal and human models [30].

Although inflammatory cytokines such as TNF have been extensively studied, emerging data have recently demonstrated the central role of IL-20 and IL-17 in the pathogenesis of psoriasis [31]. IL-17 is secreted by a new subclass of CD4⁺ cells, the Th17 cell, and plays an important role in the pathogenesis of psoriasis

and broadly activates inflammation in a variety of organ systems [32,33]. For example, IL-17 is also elevated in the sera of patients with unstable CAD [34] and is also preferentially expressed in animal models of aged coronary arteries that are susceptible to ischemia [35].

Critical to sustaining chronic inflammation and epidermal hyperproliferation in psoriasis is angiogenesis. Immuno-cytes and keratinocytes in psoriatic skin produce angiogenic factors, such as VEG-F, which promote angiogenesis and endothelial cell activation. VEG-F levels are increased in plaques of psoriasis and serum concentration of VEG-F correlates with clinical severity of disease [24[•]]. VEG-F is also increased in hyperinsulinemic states like metabolic syndrome in which adipocytes are its primary source [36[•]]. Therefore, it is possible that hyperinsulinemic states such as obesity and metabolic syndrome may promote susceptibility to psoriasis or exacerbate existing psoriasis not only through their aforementioned role in promoting inflammation, but also through increased and sustained levels of circulating VEGF. Decades of chronic angiogenesis necessary to maintain the psoriasis phenotype could also theoretically be related to cardiovascular disorders through exhausting the pool of endothelial precursor cells (EPCs) in the bone marrow, which are believed to play a critical role in maintenance of endothelial integrity, function, and repair [37[•]]. Furthermore, many of the inflammatory mediators and cell adhesion molecules increased in psoriasis can directly promote endothelial cell activation and dysfunction, leading to cardiovascular disease [38[•]]. Consistent with this hypothesis, patients with psoriatic arthritis without cardiovascular risk factors or clinically evident cardiovascular disease have been shown to exhibit endothelial dysfunction [39[•]].

Chronic psoriasis also impacts oxidative metabolic pathways which may have systemic implications, especially with respect to atherosclerosis and MI. Inflamed psoriatic skin generates free radicals, reactive oxygen species (ROS) and results in superoxide anion liberation [7]. On a cellular level, even patients with mild psoriasis display disequilibrium between markers of oxidative stress and antioxidants [27,40]. Psoriasis may further promote oxidative stress through an association with decreased folic acid levels and increased homocysteine levels [41,42].

Finally, genetics play a critical role in susceptibility to psoriasis and metabolic disorders. Over 20 genetic loci containing varying numbers of genes, many of which have no known function, have been associated with psoriasis susceptibility [43]. Of these, several are also associated with susceptibility to metabolic diseases. For instance, the psoriasis susceptibility loci PSORS2, PSORS3, and PSORS4 are also associated with loci of

susceptibility for metabolic syndrome, type 2 diabetes, familial hyperlipidemia, and cardiovascular disease [37,44–48]. Furthermore, individual genes associated with psoriasis such as CDKAL1, which has no known function, are also associated with type 2-diabetes [49,50]. Finally, genes with known function in cardiovascular risk, such as the ApoE4 isoform of ApoE are significantly more prevalent in patients with chronic plaque and guttate psoriasis than in controls [51].

Conclusion

The scientific evidence linking psoriasis to metabolic disorders and cardiovascular disease is rapidly expanding. On the basis of existing knowledge, new guidelines have been issued aimed at actively identifying metabolic disease and other cardiovascular risk factors in patients with psoriasis so that they may be properly addressed [52]. Additional well designed epidemiological studies in broadly representative psoriasis populations are necessary to determine: the role of metabolic disorders as a risk factor in developing psoriasis; the role of comorbid metabolic disorders in modifying the severity of existing psoriasis; the role of psoriasis activity and severity as an independent risk factor for developing metabolic disorders, atherosclerosis, and MI; and the role of psoriasis treatment in altering the risk of developing these serious morbidities are urgently needed. Additional translational studies are necessary to dissect the relative contributions of the various pathomechanisms linking these disorders in order to better inform treatment and prevention strategies; and, study designs should also seek to determine which biomarkers are most important in predicting the development of metabolic disorders, atherosclerosis, and MI in patients with psoriasis. Ultimately, such studies are critical to the rational development and implementation of strategies to improve psoriasis outcomes.

Acknowledgement

This work was supported in part by Grant no. K23-AR051125 (JMG).

Dr. Gelfand has grants from Amgen, Centocor, and Abbott; he is a consultant for Amgen, Centocor, and Genentech. Dr Azfar has no financial disclosure.

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 495–496).

- 1 Gelfand JM, Troxel A, Lewis JD, *et al.* The risk of mortality in patients with psoriasis: results from a population-based study. *Arch Dermatol* 2007; 143:1493–1498.

This study demonstrates that patients with severe psoriasis die about 3–4 years younger than patients without psoriasis.

- 2 Grundy SM, Cleeman JI, Daniels SR, *et al.* Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. *Cur Opin Cardiol* 2006; 21:1–6.
 - 3 Gisondi P, Tessari G, Conti A, *et al.* Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. *Br J Dermatol* 2007; 157:68–73.
- This study is notable for using well-accepted definitions of metabolic syndrome in its analysis.
- 4 Sommer DM, Jenisch S, Suchan M, *et al.* Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. *Arch Dermatol Res* 2006; 298:321–328.
 - 5 Cohen AD, Sherf M, Vidavsky L, *et al.* Association between psoriasis and the metabolic syndrome. *Dermatol* 2008; 216:152–155.
 - 6 Akhyani M, Ehsani AH, Robati RM, Robati AM. The lipid profile in psoriasis: a controlled study. *J Eur Acad Dermatol Venereol* 2007; 21:1330–1332.
 - 7 Solak Tekin N, Tekin IO, Barut F, Sipahi EY. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. *Mediators Inflamm* 2007; 2007:1–5.
 - 8 Cohen AD, Gilutz H, Henkin Y, *et al.* Psoriasis and the metabolic syndrome. *Acta Dermatol Venereol* 2007; 87:506–509.
 - 9 Farshchian M, Zamanian A, Farshchian M, *et al.* Serum lipid level in Iranian patients with psoriasis. *J Eur Acad Dermatol Venereol* 2007; 2007:802–805.
 - 10 Mallbris L, Granath F, Hamsten A, Ståhle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. *J Am Acad Dermatol* 2006; 54:614–621.
 - 11 Neimann AL, Shin DB, Wang X, *et al.* Prevalence of cardiovascular risk factors in patients with psoriasis. *J Amer Acad Dermatol* 2006; 55:829–835.
 - 12 Sterry W, Strober BE, Menter A, on behalf of the International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. *Br J Dermatol* 2007; 157:649–655.
- An excellent review.
- 13 Herron MD, Hinkley M, Hoffman MS, *et al.* Impact of obesity and smoking on psoriasis presentation and management. *Arch Dermatol* 2005; 141:1527–1534.
 - 14 Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. *Arch Int Med* 2007; 167:1670–1675.
- A rigorously performed study demonstrating that obesity is a risk factor for incident psoriasis.
- 15 Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. *Arch Dermatol* 2007; 143:1559–1565.
- This study evaluates risk factors for incident psoriasis in the general population.
- 16 Naldi L, Chatenoud L, Linder D, *et al.* Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. *J Invest Dermatol* 2005; 125:61–67.
 - 17 Shapiro J, Cohen AD, David M, *et al.* The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. *J Am Acad Dermatol* 2006; 56:629–634.
 - 18 Boehncke S, Thaci D, Beschmann H, *et al.* Psoriasis patients show signs of insulin resistance. *Br J Dermatol* 2007; 157:1249–1251.
- One of the few studies to directly measure markers of insulin resistance in patients with psoriasis.
- 19 Han C, Robinson DW Jr, Hackett MV, *et al.* Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. *J Rheumatol* 2006; 33:2167–2172.
 - 20 Kurd SK, Richardson S, Gelfand JM. Update on the epidemiology and systemic treatment of psoriasis. *Expert Rev Clin Immunol* 2007; 3:171–185.
 - 21 Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis. *Expert Rev Dermatol* 2006; 1:63–75.
 - 22 Ludwig RJ, Herzog C, Rostok A, *et al.* Psoriasis: a possible risk factor for development for coronary artery calcification. *Br J Dermatol* 2007; 156:271–276.
- This study demonstrates that psoriasis is associated with coronary artery disease independent of traditional risk factors.
- 23 Gelfand JM, Neimann AL, Shin DB, *et al.* Risk of myocardial infarction in patients with psoriasis. *J Am Med Assoc* 2006; 296:1735–1741.
 - 24 Griffiths CEM, Barker JN. Pathogenesis and clinical features of psoriasis. *Lancet* 2007; 370:263–271.
- An excellent review.
- 25 O'Malley T, Ludlam CA, Riemersma RA, Fox KAA. Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1). Potential risk factor for the acute coronary syndromes. *Eur Heart J* 2001; 22:1226–1234.

- 26 Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. *Arterioscler Thromb Vasc Biol* 2007; 27:2276–2283. An excellent review.
- 27 Wakkee M, Thio HB, Prens EP, *et al.* Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. *Atherosclerosis* 2007; 190:1–7.
- 28 Romanowska M, al Yacoub N, Seidel H, *et al.* PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. *J Invest Dermatol* 2008; 128:110–124.
- 29 Yoo H, Kim S-J, Kim Y, *et al.* Insulin-like growth factor-II regulates the 12-lipoxygenase gene expression and promotes cell proliferation in human keratinocytes via the extracellular regulatory kinase and phosphatidylinositol 3-kinase pathways. *Int J Biochem Cell Biol* 2007; 39:1248–1259. This study investigates the potential role of IGF-II in the pathophysiology of psoriasis.
- 30 Zaina S, Nilsson J. Insulin-like growth factor II and its receptors in atherosclerosis and in conditions predisposing to atherosclerosis. *Cur Opin Lipidol* 2003; 14:483–489.
- 31 Wei CC, Hsu YH, Li HH, *et al.* IL-20: biological functions and clinical implications. *J Biomed Sci* 2006; 13:601–612.
- 32 Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. *Mediators Inflamm* 2005; 2005:273–279.
- 33 Sabat R, Phillip S, Hoflich C, *et al.* Immunopathogenesis of psoriasis. *Exper Dermatol* 2007; 16:779–798.
- 34 Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-8 in unstable coronary artery disease. *Coron Artery Dis* 2006; 17:699–706.
- 35 Csiszar A, Ungvari Z, Koller A, *et al.* Aging-induced proinflammatory shift in cytokine expression profile in rat coronary arteries. *FASEB J* 2003; 17:1183–1185.
- 36 Cao Y. Angiogenesis modulates adipogenesis and obesity. *J Clin Invest* 2007; 117:2362–2368. An excellent review.
- 37 Shantsila E, Watson T, Lip GYH. Endothelial progenitor cells in cardiovascular disorders. *J Am Coll Cardiol* 2007; 49:741–752. An excellent review.
- 38 Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical reference. *Circulation* 2007; 115:1285–1295. An excellent review.
- 39 Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, *et al.* Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. *Arthritis Rheum* 2007; 57:287–293. One of the very few studies to explore endothelial dysfunction in patients with psoriatic disease.
- 40 Wozniak A, Drewa G, Krzyzyska-Maliniowska E, *et al.* Oxidant-antioxidant balance in patients with psoriasis. *Med Sci Monit* 2007; 13:CR30–CR33.
- 41 Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. *J Thromb Haemost* 2005; 3:1646–1654.
- 42 Malerba M, Gisondi P, Radaeli A, *et al.* Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. *Br J Dermatol* 2006; 155:1165–1169.
- 43 Richardson SK, Gelfand JM. Update on the natural history and systemic treatment of psoriasis. *Adv Dermatol* (in press).
- 44 Bowden DW, Rudock M, Ziegler J, *et al.* Coincident linkage of type 2 diabetes, metabolic syndrome and measures of cardiovascular disease in a genome scan of the diabetes heart study. *Diabetes* 2006; 55:1985–1994.
- 45 Das SK, Elbein SC. The search for type 2 diabetes susceptibility loci: the chromosome 1q story. *Curr Diab Rep* 2007; 7:154–164.
- 46 Ng MC, Miyake K, So WY, *et al.* The linkage and association of the gene encoding upstream stimulatory factor 1 with type 2 diabetes and metabolic syndrome in the Chinese population. *Diabetologia* 2005; 48:2018–2024.
- 47 Parker A, Meyer J, Lewitzky S, *et al.* A gene conferring susceptibility to type 2 diabetes in conjunction with obesity is located on chromosome 18p11. *Diabetes* 2001; 50:675–680.
- 48 Suviolahti E, Lilja HE, Pajukanta P. Unraveling the complex genetics of familial combined hyperlipidemia. *Ann Med* 2006; 38:337–351.
- 49 Steinthorsdottir V, Thorleifsson G, Reynisdottir I, *et al.* A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. *Nature Genet* 2007; 39:770–775.
- 50 Wolf N, Quaranta M, Prescott NJ, *et al.* Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. *J Med Genet* 2008; 45:114–116. An important study linking susceptibility loci for psoriasis and diabetes.
- 51 Campalani E, Allen MH, Fairhurst D, *et al.* Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. *Br J Dermatol* 2006; 154:345–352.
- 52 Kimball AB, Gladman D, Gelfand JM, *et al.* National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. *J Am Acad Dermatol* 2008 [Epub ahead of print]. An important consensus statement.